IDEAYA Biosciences, Inc. (IDYA)
38.41
-0.20
(-0.52%)
USD |
NASDAQ |
Sep 18, 16:00
38.41
0.00 (0.00%)
After-Hours: 20:00
IDEAYA Biosciences Enterprise Value : 2.902B for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 2.902B |
| September 17, 2026 | 2.921B |
| September 16, 2026 | 2.837B |
| September 15, 2026 | 2.830B |
| September 14, 2026 | 2.866B |
| September 11, 2026 | 2.823B |
| September 10, 2026 | 2.810B |
| September 09, 2026 | 2.896B |
| September 08, 2026 | 2.944B |
| September 04, 2026 | 3.042B |
| September 03, 2026 | 3.052B |
| September 02, 2026 | 3.072B |
| September 01, 2026 | 3.051B |
| August 31, 2026 | 3.065B |
| August 28, 2026 | 3.066B |
| August 27, 2026 | 3.226B |
| August 26, 2026 | 3.208B |
| August 25, 2026 | 3.294B |
| August 24, 2026 | 3.059B |
| August 21, 2026 | 3.024B |
| August 20, 2026 | 2.970B |
| August 19, 2026 | 2.946B |
| August 18, 2026 | 2.856B |
| August 17, 2026 | 2.722B |
| August 14, 2026 | 2.699B |
| Date | Value |
|---|---|
| August 13, 2026 | 2.735B |
| August 12, 2026 | 2.762B |
| August 11, 2026 | 2.751B |
| August 10, 2026 | 2.741B |
| August 07, 2026 | 2.768B |
| August 06, 2026 | 2.693B |
| August 05, 2026 | 2.674B |
| August 04, 2026 | 2.680B |
| August 03, 2026 | 2.612B |
| July 31, 2026 | 2.622B |
| July 30, 2026 | 2.708B |
| July 29, 2026 | 2.630B |
| July 28, 2026 | 2.685B |
| July 27, 2026 | 2.744B |
| July 24, 2026 | 2.612B |
| July 23, 2026 | 2.692B |
| July 22, 2026 | 2.573B |
| July 21, 2026 | 2.669B |
| July 20, 2026 | 2.617B |
| July 17, 2026 | 2.671B |
| July 16, 2026 | 2.663B |
| July 15, 2026 | 2.741B |
| July 14, 2026 | 2.733B |
| July 13, 2026 | 2.684B |
| July 10, 2026 | 2.765B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Xencor, Inc. | 1.551B |
| UroGen Pharma Ltd. | 2.200B |
| MeiraGTx Holdings Plc | 1.217B |
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -112.45M |
| Revenue (Quarterly) | 8.857M |
| Total Expenses (Quarterly) | 121.31M |
| EPS Diluted (Quarterly) | -1.222 |
| Gross Profit Margin (Quarterly) | 87.21% |
| Profit Margin (Quarterly) | -1.27K% |
| Earnings Yield | -5.06% |
| Normalized Earnings Yield | -5.059 |